Hepion Pharmaceuticals, Inc. Stock: price and insider trades · United States
4 insiders bought €464k of shares over the last 90 days, the latest by Fisher Danina, filed 02 Oct 2026.
Hepion Pharmaceuticals, Inc.: what insiders have been doing
Every trade that managers of Hepion Pharmaceuticals, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. Between 8 November 2025 and 8 November 2026, 4 insiders published 6 filings.
Only purchases show up on the open market, 6 purchases in all worth €677k, filed by 4 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a purchase of €347k by LoPriore Vincent S, published on 12 August 2026, equal to 6.9% of the market capitalisation. On the buying side, the filings list 3 senior executives and 1 chief executive among the declarants.
Across the 281 companies tracked on its exchange, the median is 8 filings; at 6 filings, this issuer sits below that mark. Our records for Hepion Pharmaceuticals, Inc. go back to 2014, with 27 purchases and no sales on the open market in total.
In the case of 5 purchases, another manager of the company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. The last purchase on record was published on 2 October 2026, which is 37 days ago. Typically, a trade is published a median of 8 days after it takes place. US insiders must file a Form 4 within two business days of a trade.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Vetoquinol SA. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- +55.0%Entry US$0.10 · Close at T+30 US$0.16
- +12.9%Entry US$0.07 · Close at T+30 US$0.08
- +12.9%Entry US$0.07 · Close at T+30 US$0.08
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 200,000 shares@ US$0.050.11% mcap100.0% of flowCommon StockSEC:0001493152-26-045526:0Canonical exit: 28 Dec 2026 (T+90)
- 500,000 shares@ US$0.050.43% mcap100.0% of flowCommon StockSEC:0001493152-26-037500:0Canonical exit: 1 Nov 2026 (T+90)
- 2,000,000 shares@ US$0.051.74% mcap13.4% of flowCommon StockSEC:0001493152-26-037489:1Canonical exit: 1 Nov 2026 (T+90)
- 2,000,000 shares@ US$0.051.74% mcap67.1% of flowCommon StockSEC:0001493152-26-037493:0Canonical exit: 1 Nov 2026 (T+90)
- 2,000,000 shares@ US$0.051.74% mcap67.1% of flowCommon StockSEC:0001493152-26-037496:0Canonical exit: 1 Nov 2026 (T+90)
- 2,000,000 shares@ US$0.051.74% mcap67.1% of flowCommon StockSEC:0001493152-26-037490:0Canonical exit: 1 Nov 2026 (T+90)
- 8,000,000 shares@ US$0.056.94% mcap67.1% of flowCommon StockSEC:0001493152-26-037489:0Canonical exit: 1 Nov 2026 (T+90)
- 1,250,000 shares@ US$0.040.74% mcap32.9% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-019028:0Canonical exit: 20 Jul 2026 (T+90)
- 1,250,000 shares@ US$0.040.74% mcap32.9% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-019027:0Canonical exit: 20 Jul 2026 (T+90)
- 5,000,000 shares@ US$0.042.94% mcap26.3% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-019029:0Canonical exit: 20 Jul 2026 (T+90)
- 1,250,000 shares@ US$0.040.74% mcap6.6% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-019029:1Canonical exit: 20 Jul 2026 (T+90)
- 1,250,000 shares@ US$0.040.74% mcap32.9% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-019202:0Canonical exit: 20 Jul 2026 (T+90)
- 2,500 shares@ US$3.05Common StockSEC:0001104659-23-121427:1Canonical exit: 25 Feb 2024 (T+90)
- 2,500 shares@ US$3.0956.4% of flowCommon StockSEC:0001104659-23-121427:0Canonical exit: 22 Feb 2024 (T+90)
- 139 shares@ US$5.450.0% of flowCommon StockSEC:0001104659-23-102209:1Canonical exit: 14 Dec 2023 (T+90)
- 861 shares@ US$5.37Common StockSEC:0001104659-23-102209:2Canonical exit: 14 Dec 2023 (T+90)
- 1,000 shares@ US$5.64Common StockSEC:0001104659-23-102209:3Canonical exit: 18 Dec 2023 (T+90)
- 1,000 shares@ US$5.8243.6% of flowCommon StockSEC:0001104659-23-102209:0Canonical exit: 14 Dec 2023 (T+90)
- 1,600 shares@ US$5.6050.8% of flowCommon StockSEC:0001104659-23-101784:0Canonical exit: 17 Dec 2023 (T+90)
- 1,600 shares@ US$5.4049.2% of flowCommon StockSEC:0001104659-23-101391:0Canonical exit: 14 Dec 2023 (T+90)
- 20,000 shares@ US$2.0040.4% of flowCommon StockSEC:0001104659-21-025199:0Canonical exit: 19 May 2021 (T+90)
- 10,000 shares@ US$2.0048.3% of flowCommon StockSEC:0001104659-21-025196:0Canonical exit: 19 May 2021 (T+90)
- 10,000 shares@ US$2.2029.3% of flowCommon StockSEC:0001104659-21-025200:0Canonical exit: 17 May 2021 (T+90)
- 20,000 shares@ US$1.9171.3% of flowCommon StockSEC:0001104659-20-137755:0Canonical exit: 18 Mar 2021 (T+90)
- 25,000 shares@ US$1.576766.4% of flowCommon StockSEC:0001104659-20-133141:0Canonical exit: 8 Mar 2021 (T+90)
25 of 45 declarations
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for liver diseases. It primarily concentrates on the research and development of innovative drugs.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
